Century Therapeutics (NASDAQ:IPSC – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Century Therapeutics to similar companies based on the strength of its earnings, profitability, valuation, institutional ownership, dividends, analyst recommendations and risk.
Insider and Institutional Ownership
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Century Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Century Therapeutics | $109.16 million | -$9.58 million | -1.82 |
| Century Therapeutics Competitors | $702.35 million | $7.52 million | -17.98 |
Century Therapeutics’ peers have higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Century Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Century Therapeutics | N/A | -45.64% | -35.94% |
| Century Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Analyst Ratings
This is a summary of current ratings for Century Therapeutics and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Century Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Century Therapeutics Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
Century Therapeutics currently has a consensus target price of $4.75, suggesting a potential upside of 307.73%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Century Therapeutics’ higher possible upside, equities research analysts clearly believe Century Therapeutics is more favorable than its peers.
Risk and Volatility
Century Therapeutics has a beta of 1.78, indicating that its share price is 78% more volatile than the S&P 500. Comparatively, Century Therapeutics’ peers have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Summary
Century Therapeutics peers beat Century Therapeutics on 7 of the 13 factors compared.
Century Therapeutics Company Profile
Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
